Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality.
Adult
Anilides
/ administration & dosage
Antiviral Agents
/ administration & dosage
Carbamates
/ administration & dosage
Cyclopropanes
Cytochrome P-450 CYP3A Inhibitors
/ administration & dosage
Drug Combinations
Egypt
Female
Hepatitis C, Chronic
/ drug therapy
Humans
Lactams, Macrocyclic
Macrocyclic Compounds
/ administration & dosage
Male
Middle Aged
Proline
/ analogs & derivatives
Prospective Studies
Renal Dialysis
Ritonavir
/ administration & dosage
Sulfonamides
Treatment Outcome
Valine
Antiviral agents
Chronic hemodialysis
Chronic hepatitis C
DAA therapy
Drug interaction
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
24
02
2019
accepted:
21
07
2019
pubmed:
1
8
2019
medline:
28
2
2020
entrez:
1
8
2019
Statut:
ppublish
Résumé
New direct-acting antiviral drugs have become the corner-stone treatment for HCV infection: they show promising results with accepted side-effects and low dropout rates. One of the available regimens is paritaprevir/ombitasvir/ritonavir (PTV/OMV/RTV). Our aim was to study the efficacy and safety of this drug regimen among HCV-positive hemodialysis patients. This prospective single-center study was performed in the Urology and Nephrology Center, Mansoura University, Egypt. Ninety-six maintenance hemodialysis patients were screened for HCV antibodies. Positive results were found in 46 patients (47.9%). HCV PCR was assessed in all HCV-antibody-positive patients; positive results were found positive for 38 (82%); all patients were HCV genotype 4. Four patients were excluded due to advanced liver cirrhosis, liver malignancy, or metastatic breast cancer. Thirty-four patients were prescribed PTV/OMV/RTV for 3 months to treat HCV. Mean age was 43.2 ± 11.9 years. Most patients were male (67.6%). There was a rapid response to treatment: HCV PCR became negative by 4 weeks after starting treatment. By 12 and 24 weeks post-DAA therapy, there was a sustained viral response (SVR 12, SVR 24) in 100% of patients with improved liver-enzyme levels. The PTV/OMV/RTV regimen was safe and effectively treated Egyptian HCV-positive genotype-4 hemodialysis patients.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
New direct-acting antiviral drugs have become the corner-stone treatment for HCV infection: they show promising results with accepted side-effects and low dropout rates. One of the available regimens is paritaprevir/ombitasvir/ritonavir (PTV/OMV/RTV). Our aim was to study the efficacy and safety of this drug regimen among HCV-positive hemodialysis patients.
METHODS
METHODS
This prospective single-center study was performed in the Urology and Nephrology Center, Mansoura University, Egypt. Ninety-six maintenance hemodialysis patients were screened for HCV antibodies. Positive results were found in 46 patients (47.9%). HCV PCR was assessed in all HCV-antibody-positive patients; positive results were found positive for 38 (82%); all patients were HCV genotype 4. Four patients were excluded due to advanced liver cirrhosis, liver malignancy, or metastatic breast cancer. Thirty-four patients were prescribed PTV/OMV/RTV for 3 months to treat HCV.
RESULTS
RESULTS
Mean age was 43.2 ± 11.9 years. Most patients were male (67.6%). There was a rapid response to treatment: HCV PCR became negative by 4 weeks after starting treatment. By 12 and 24 weeks post-DAA therapy, there was a sustained viral response (SVR 12, SVR 24) in 100% of patients with improved liver-enzyme levels.
CONCLUSION
CONCLUSIONS
The PTV/OMV/RTV regimen was safe and effectively treated Egyptian HCV-positive genotype-4 hemodialysis patients.
Identifiants
pubmed: 31363959
doi: 10.1007/s11255-019-02246-7
pii: 10.1007/s11255-019-02246-7
doi:
Substances chimiques
Anilides
0
Antiviral Agents
0
Carbamates
0
Cyclopropanes
0
Cytochrome P-450 CYP3A Inhibitors
0
Drug Combinations
0
Lactams, Macrocyclic
0
Macrocyclic Compounds
0
Sulfonamides
0
ombitasvir
2302768XJ8
Proline
9DLQ4CIU6V
Valine
HG18B9YRS7
Ritonavir
O3J8G9O825
paritaprevir
OU2YM37K86
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1639-1647Références
Nephron Clin Pract. 2006;103(1):c8-11
pubmed: 16374034
J Viral Hepat. 2008 Feb;15(2):79-88
pubmed: 18184190
Am J Kidney Dis. 2008 Feb;51(2):263-77
pubmed: 18215704
Aliment Pharmacol Ther. 2014 Jan;39(2):137-47
pubmed: 24251930
J Hepatol. 2014 Nov;61(1 Suppl):S45-57
pubmed: 25086286
Gastroenterology. 2016 Jun;150(7):1590-1598
pubmed: 26976799
Eur J Drug Metab Pharmacokinet. 2017 Apr;42(2):333-339
pubmed: 27165046
J Hepatol. 2017 Jan;66(1):153-194
pubmed: 27667367
Nephrology (Carlton). 2018 May;23(5):446-452
pubmed: 28339162
Adv Ther. 2017 Jun;34(6):1449-1465
pubmed: 28536999
J Gastroenterol. 2018 Jan;53(1):119-128
pubmed: 28560477
Nephrology (Carlton). 2017 Jul;22(7):562-565
pubmed: 28621007
Ther Clin Risk Manag. 2017 Jun 22;13:733-738
pubmed: 28790832
J Hepatol. 2018 Nov;69(5):1178-1187
pubmed: 30006068
Kidney Int Rep. 2018 Oct 09;4(2):257-266
pubmed: 30775622